Cases where pregnant mothers have a history of psychiatric conditions and are in the routine of taking medications, often are at crossroads when it comes to deciding whether or not to continue the course during pregnancy. How it would affect the baby is a major concern for every mother:

2. Epilepsy drugs and birth defects

When it comes to the case of epilepsy, it is rather important that women continue their medication during pregnancy, for their health. Not only that, but research for more than two decades have shown that children exposed to these medications in the womb can be at a higher risk of having a malformation or birth defect.

But this recent joint study conducted by researchers from the universities of Liverpool and Manchester has come up with a breather – the study could successfully attach a certain group of epilepsy medication to the birth defects, and excluding many others from causing the risk.

The majority of epilepsy -affected women with will be required to continue anti-epileptic drug treatment during a pregnancy and therefore the only step possible is to carefully choose treatment methods and collaboratively find a balance between securing maternal health whilst minimizing fetal risk.

It was found that exposure in the womb to sodium valproate based medications were associated with a 10% chance of the child having a birth defect, a percentage that rose as the dose of the drug increased.

But the hearty aspect of the study is that it also found that children exposed to lamotrigine or levetiracetam were not found to be at an increased risk of significant birth defects and had lower risks when  compared to the children exposed to drugs such as carbamazepine, phenytoin or topiramate. 

This is a really important result that should be considered during consultations about epilepsy treatment choices for pregnant women or those of childbearing potential.

As per the current evidence, levetiracetam and lamotrigine appear to be the AEDs associated with the lowest level of risk.